RBC Capital lowered the firm’s price target on Bausch Health to $11 from $12 and keeps a Sector Perform rating on the shares ahead of its Q1 results. Investor focus is expected to fall on a potential Bausch + Lomb (BLCO) distribution to Bausch Health shareholders and the factors influencing such a decision, the analyst tells investors in a research note. Following the Appellate Court’s ruling, Bausch Healt stands in a stronger position to move forward with a potential Bausch + Lomb distribution, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHC:
- Bausch Health put volume heavy and directionally bearish
- Jefferies healthcare analyst holds an analyst/industry conference call
- Bausch Health Wins Patent Appeal for XIFAXAN
- Bausch Health says ruling prevents FDA approval of Norwich ANDA until 2029
- Bausch ‘win’ in Xifaxan case clears major hurdle ahead of spin, says Jefferies
